

## Bibliografía

1. Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, Van Adelsberg J, Fiore S, *et al.* Sarilumab, a fully human monoclonal antibody against IL-6R  $\alpha$  in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA MOBILITY Part A trial. *Ann Rheum Dis.* 2014;73:1626-34.
2. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al.* Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol.* 2015;67:1424-37.
3. Fleischmann R, Van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, *et al.* Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active Rheumatoid Arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors. *Arthritis Rheumatol.* 2017;69:277-90.
4. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NMH, *et al.* Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis.* 2017;76:840-7.
5. Hernández Cruz B. Eficacia de sarilumab en la artritis reumatoide. *Reumatol Clin Supl.* 2018;14:22-34.
6. Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND). ClinicalTrials.gov Identifier: NCT01146652. [Internet]. Sanofi; 2010. [Actualizado el 29 Ene 2020]. [Fecha de acceso: 7 Feb 2020]. Disponible en: [www.clinicaltrials.gov/ct2/show/NCT01146652](http://www.clinicaltrials.gov/ct2/show/NCT01146652)
7. Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, Van Hoogstraten, *et al.* Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. *Rheumatology (Oxford).* 2019;58:849-58.
8. Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF- $\alpha$  Blockers. ClinicalTrials.gov Identifier: NCT01217814. [Internet]. Sanofi; 2010. [Actualizado el 1 Sep 2017]. [Fecha de acceso: 7 Feb 2020]. Disponible en: [www.clinicaltrials.gov/ct2/show/NCT01217814](http://www.clinicaltrials.gov/ct2/show/NCT01217814)
9. Wells AF, Parrino J, Mangan EK, Paccaly A, Lin Y, Xu C, *et al.* Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. *Rheumatol Ther.* 2019;6:339-52.
10. Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, *et al.* Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. *RMD Open.* 2019;5:e000887.
11. Burmester GR, Lin Y, St John G, Wang S, Gómez Reino JJ, Maldonado Cocco JA, *et al.* Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARDs in patients with rheumatoid arthritis. [Abstract SAT0172]. *Ann Rheum Dis.* 2018;77:946-7.
12. Curtis JR, St John G, Pannucci M, Lin Y, Maldonado-Cocco JA, Huizinga T, *et al.* Reductions in absolute neutrophil count with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety. [Abstract 1940]. En: 2018 ACR/ARHP Annual Meeting. ACR; 2018.
13. Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, *et al.* 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. *Reumatol Clin.* 2015;11:279-94.
14. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester G, Dougados M, Kerschbaumer A, *et al.* EULAR recommendations for the management of rheumatoid Arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020. pii: annrheumdis-2019-216655. [Epub ahead of print].
15. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, *et al.* 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016;68:1-26.
16. Fleischmann R, Selmi C, González-Gay M, Van Hoogstraten H, Hagino O, Rajput T, *et al.* Glucocorticoid dose is progressively reduced in patients with RA receiving sarilumab: Results from the open-label EXTEND study. [Abstract 1379]. En: 2019 ACR/ARHP Annual Meeting. ACR; 2019.
17. Curtis J, Lin Y, Thangavelu K, Stanislav M, St John G, Gómez-Centeno A, *et al.* Withdrawal of conventional synthetic disease-modifying antirheumatic drugs in the Sarilumab open-label EXTEND study: Efficacy and safety analysis. [Abstract 2351]. En: 2019 ACR/ARHP Annual Meeting. ACR; 2019.
18. Tesser J, St John G, Kimura T, Fiore S, Rischmueller M, Maldonado-Cocco JA, *et al.* Liver function test levels with sarilumab treatment in phase 3 trials: analysis by baseline liver function test level. [Abstract 2529]. En: 2018 ACR/ARHP Annual Meeting. ACR; 2018.
19. Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez Centeno A, *et al.* Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. *RMD Open.* 2019;5:e001017.
20. Curtis J, Aletaha D, Burmester G, Ford K, Van Hoogstraten H, Leher H, *et al.* Low probability of clinical worsening following switching biologic DMARD in patients with RA and partial response to adalimumab. [Abstract 1387]. En: 2019 ACR/ARHP Annual Meeting. ACR; 2019.

21. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. [Abstract 2468]. En: 2017 ACR/ARHP Annual Meeting. ACR; 2017.
22. Verschueren P, Emery P, van Hoogstraten H, Dong Q, Mangan EK, den Broeder A. Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. [Abstract THU0215]. *Ann Rheum Dis.* 2018;77:327-8.
23. Boyapati A, Msihid J, Schwartzman S, Choy E, Genovese MC, Burmester GR, *et al.* High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. [Abstract L08]. En: 2018 ACR/ARHP Annual Meeting. ACR; 2018.
24. Strand V, Msihid J, Kimura T, Boyapati A, St John G, Wei W. High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among rheumatoid arthritis patients with inadequate response to methotrexate. [Abstract 1378]. En: 2019 ACR/ARHP Annual Meeting. ACR; 2019.